之前我写了篇关于ICL晶体植入手术，提到与角膜激光手术相比，它具有不用切削角膜、矫正范围广、术后视觉质量更优以及对 ...

Barclays raised the firm’s price target on ICL (ICL) to $7 from $6 and keeps an Equal Weight rating on the shares. After a volatile start to crop prices and agriculture input pricing ...

In a report released today, Lisa De Neve from Morgan Stanley maintained a Hold rating on Icl (ICL – Research Report), with a price target of $5.40. The company’s shares closed yesterday at $5.90.

Blue-chip tech stocks are a big part of President Donald Trump's portfolio, according to his latest financial disclosures.